Clinical studies of beta-thioguanine deoxyriboside alone and in combination with arabinosyl cytosine.
Beta-thioguanine deoxyriboside (betaTGdR) is a purine nucleoside derivative which was studied alone or in combination with arabinosyl cytosine (Ara-C) in patients with solid tumors and acute leukemia. No significant responses were observed in 22 patients with solid tumors. The response rate with betaTGdR alone in acute leukemia was 26% and in combination with Ara-C was 24%. Responses were generally of short duration. Toxicity included myelosuppression, nausea, stomatitis, hyperpigmentation, photosensitivity, and liver function abnormalities.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D003849:Deoxyguanosine / Q000031:analogs & derivatives; D003853:Deoxyribonucleosides / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006151:Guanosine / Q000009:adverse effects; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013872:Thionucleosides; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
D003853:Deoxyribonucleosides; D013872:Thionucleosides; D003561:Cytarabine; D006151:Guanosine; C010438:beta-2'-deoxythioguanosine; D013866:Thioguanine; D003849:Deoxyguanosine